超声心动图结合生物标记物在非瓣膜性心房颤动患者左心房血栓诊断中的意义

赵艳春; 宝金才; 高翔; 王婧; 陈美凤; 田海萍

doi:10.13201/j.issn.1001-1439.2020.09.014

超声心动图结合生物标记物在非瓣膜性心房颤动患者左心房血栓诊断中的意义

- 内蒙古医科大学附属医院心内科(呼和浩特, 010059)
基金项目:
内蒙古自治区卫生计生委科研项目(No:201702094)

内蒙古自治区自然科学基金项目(No:2014MS0876)

详细信息

通讯作者: 田海萍,E-mail:thp19770515@126.com

中图分类号: R541.7

收稿日期: 2020-05-04

Echocardiography combined with biomarkers in the diagnosis of left atrial thrombosis in patients with nonvalvular atrial fibrillation

- Department of Cardiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010059, China

More Information

Corresponding author: TIAN Haiping, E-mail: thp19770515@126.com

Received Date: 04 May 2020

摘要

摘要: 目的:通过联合检测左心耳流速、左房前后径及血清生物学标记物,探讨其对非瓣膜性房颤(NVAF)患者左心房血栓的诊断意义。方法:入选2017年12月-2019年12月内蒙古医科大学附属医院收治的NVAF患者,通过食管超声心动图结果将患者分为无血栓组和血栓组,并测量左心耳流速,经胸超声心动图测量患者的左房前后径及左室射血分数。计算CHA2DS2-VASc评分,检测D-二聚体、同型半胱氨酸及脑钠肽前体。结果:①两组患者一般情况(年龄、性别、高血压、糖尿病)及CHA2DS2-VASc评分无统计学差异(P>0.05)。②血栓组患者左心耳流速减慢、左房前后径增大、LVEF减低(P<0.05)。单因素Logistic回归分析显示,左心耳流速、左房前后径、左室射血分数在左心房血栓诊断中具有重要意义。③血栓组患者血清D-二聚体、脑钠肽前体、同型半胱氨酸高于无血栓组。④多因素logistic回归分析显示,左心耳流速(OR=0.83,95%CI:0.78~10.87,P<0.001)、左房前后径(OR=1.09,95%CI:1.00~1.18,P=0.044)是左心房血栓诊断的重要指标。当左心耳流速截点值为25.5 cm/s时,诊断左心房血栓形成的灵敏度和特异度分别为98%、45%,ROC曲线下面积为0.939。左心耳流速联合左房前后径诊断左心房血栓形成ROC曲线下面积为0.945。在二者基础上联合D-二聚体及脑钠肽前体诊断左心房血栓形成ROC曲线下面积为0.948。结论:左心耳流速减慢在NVAF患者左心房血栓诊断中具有重要作用。左心耳流速联合左心房前后径及血清D-二聚体、脑钠肽前体,提高了对NVAF患者左心房血栓的诊断能力,其敏感性及有效性增加。
- 心房颤动 /
- 左心耳流速 /
- 左心房血栓 /
- 左心结构及功能 /
- 生物学标记物
Abstract: Objective:To explore the diagnostic significance of left atrial appendage velocity(LAAV),Left atrial diameter(LAD) and serum biomarkers in patients with non-valvular atrial fibrillation(NVAF).Method:Patients with NVAF admitted to the Affiliated Hospital of Inner Mongolia Medical University from December 2017 to December 2019 were divided into non-thrombotic group and thrombotic group by transesophageal echocardiography(TEE).The LAAV was measured,and the LAD and LVEF were measured by transthoracic echocardiography(TTE).We calculated CHA2 DS2-VASc score,and measured D-dimer and pro-brain natriuretic peptide.Result:① There was no significant difference in general condition(age,sex,hypertension,diabetes) and CHA2 DS2-VASc score between the two groups(P>0.05). ② LAAV decreased,LAD increased and LVEF decreased in thrombus group(P<0.05).Univariate logistic regression analysis showed that LAAV,LAD and LVEFhad played the important roles in the diagnosis of LAT. ③ Serum D-dimer,pro-brain natriuretic peptide and homocysteine in patients with thrombosis were higher than those in patients without thrombosis. ④ Multivariate logistic regression analysis showed that LAAV(OR=0.83,95%CI:0.78-10.87,P<0.001) and LAD(OR=1.09,95%CI:1.00-1.18,P=0.044) were important indicators in the diagnosis of LAT.When LAAV was 25.5 cm/s,the sensitivity and specificity of diagnosing LAT were 98% and 45%,and the area under ROC curve was 0.939.The area under ROC curve of LAAV combined LAD diagnosis LAT was 0.945.On the basis of both,combined with D-dimer and pro-brain natriuretic peptide,the area under ROC curve for diagnosing LAT was 0.948.Conclusion: The slow velocity of left atrial appendage plays an important role in the diagnosis of left atrial thrombus in patients with NVAF. The LAAV combined withLAD,serum D-dimer and pro-brain natriuretic peptide precursor,can improve the diagnostic ability,sensitivity and effectiveness of LAT in NVAF patients.
- atrial fibrillation /
- left atrial appendage velocity /
- left atrial thrombus /
- left ventricular structure and function /
- biological markers

HTML全文

参考文献(24)

[1]	Pistoia F,Sacco S,Tiseo C,et al.The epidemiology of atrial fibrillation and stroke[J].Cardiol Clin,,2016,34(2):255-268.
[2]	Bai Y,Wang YL,Shantsila A,et al.The global burden of atrial fibrillation and stroke:a systematic review of the clinical epidemiology of atrial fibrillation in Asia[J].Chest,2017,152(4):810-820.
[3]	Toshiyasu O,Ryu M,Fumi K,et al.Left atrial size and long-term risk of recurrent stroke after acute ischemic stroke in patients with nonvalvular atrial fibrillation[J].Am Heart Assoc,2017,6(8):e006402.
[4]	Chiang CE,Okumura K,Zhang S,et al.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J].J Arrhythm,2017,33(4):345-367.
[5]	马长生.2019年心房颤动治疗新进展[J].临床心血管病杂志,2019,35(11):967-971.
[6]	陈雪梅.非瓣膜性房颤患者血栓栓塞风险评分与血压等级的相关性[D].南华大学,2019.
[7]	Perkiomaki JS,Nortamo S,Ylitalo A,et al.Ambulatory blood pressure characteristics and long-term risk for atrial fibrillation[J].Am J Hypertens,2017,30(3):264-270.
[8]	Khan MN,Usmani A,Noor S,et al.Low incidence of left atrial or left atrial appendage thrombus in patients with paroxysmal atrial fibrillation and normal EF who present for pulmonary vein antrum isolation procedure[J].J Cardiovasc Electrophysiol,2008,19(4):356-358.
[9]	Lee JM,Kim JB,Uhm JS,et al.Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA2DS2-VASc scores[J].Heart Rhythm,2017,14(9):1297-1301.
[10]	Rowlens M.Melduni,MD,Real-time pathophysiologic correlates of left atrial appendage thrombus in patients who underwent transesophageal-guided electrical cardioversion for atrial fibrillation[J].Am J Cardiol,2018,121(12):1540-1547.
[11]	Bart MD,Dawn OK.Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke:A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association American Heart Association Stroke Council and Council on Epidemiology and Prevention[J].Stroke,2016,47(2):581-641.
[12]	Guo Y,Lip GY,Apostolakis S.Inflammatory Biomarkers and Atrial Fibrillation:Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism[J].Curr Vasc Pharmacol,2015,13(2):192-201.
[13]	Zacharia E,Papageorgiou N.Inflammatory biomarkers in atrial fibrillation[J].Curr Med Chem,2019,26(5):837-854.
[14]	李雪博,李昌海,王孝锋,等.心外膜脂肪组织、肥胖与心房颤动的研究进展[J].临床心血管病杂志,2020,36(2):193-195.
[15]	Wyse DG,Van Gelder IC,Ellinor P T,et al.Lone atrial fibrillation:does it exist[J]J Am Coll Cardiol,2014,63(17):1715-1723.
[16]	Schnabel RB,Yin X,Gona P,et al.50 year trends in atrial fibrillation prevalence,incidence,risk factors,and mortality in the Framingham Heart Study:a cohort study[J].Lancet,2015,386(9989):154-162.
[17]	Kallistratos MS,Poulimenos LE,Manolis AJ.Atrial fibrillation and arterial hypertension[J].Pharmacol Res,2018,128:322-326.
[18]	田刚,刘蕾.高血压如影随形的杀手——心房颤动[J].临床心血管病杂志,2019,35(8):683-686.
[19]	Aune D,Feng T,Schlesinger S,et al.Diabetes mellitus,blood glucose and the risk of atrial fibrillation:A systematic review and meta-analysis of cohort studies[J].J Diabetes Complications,2018,32(5):501-511.
[20]	Xing XF,Liu NN,Han YL,et al.Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography[J].Medicine (Baltimore),2018,97(26):e11117.
[21]	Michael S,Garshick K,Jennifer M,et al.Average E' Velocity on transthoracic echocardiogram is a novel predictor of left atrial appendage sludge or thrombus in patients with atrial fibrillation[J].Echocardiography,2018,35(12):1939-1946.
[22]	Costa C,Gonzalez-Alujas T,Valente F,et al.Left atrial strain:a new predictor of thrombotic risk and successful electrical cardioversion[J].Echo Res Pract,2016,3(2):45-52.
[23]	Roldán V,Rivera-Caravaca JM,Shantsila A,et al.Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers[J].Ann Med,2018,50(1):26-34.
[24]	Khan AA,Lip GYH,The prothrombotic state in atrial fibrillation:pathophysiological and management implications[J].Cardiovasc Res,2019,115(1):31-45.